145 related articles for article (PubMed ID: 23200635)
1. Alternative generation of MHC class II-restricted epitopes: not so exceptional?
Eisenlohr LC
Mol Immunol; 2013 Sep; 55(2):169-71. PubMed ID: 23200635
[TBL] [Abstract][Full Text] [Related]
2. Beyond the classical: influenza virus and the elucidation of alternative MHC class II-restricted antigen processing pathways.
Eisenlohr LC; Luckashenak N; Apcher S; Miller MA; Sinnathamby G
Immunol Res; 2011 Dec; 51(2-3):237-48. PubMed ID: 22101673
[TBL] [Abstract][Full Text] [Related]
3. Activation of Dendritic Cells Alters the Mechanism of MHC Class II Antigen Presentation to CD4 T Cells.
Cho KJ; Ishido S; Eisenlohr LC; Roche PA
J Immunol; 2020 Mar; 204(6):1621-1629. PubMed ID: 31996461
[TBL] [Abstract][Full Text] [Related]
4. Loss in CD4 T-cell responses to multiple epitopes in influenza due to expression of one additional MHC class II molecule in the host.
Nayak JL; Sant AJ
Immunology; 2012 Aug; 136(4):425-36. PubMed ID: 22747522
[TBL] [Abstract][Full Text] [Related]
5. Influenza A virus infection-induced macroautophagy facilitates MHC class II-restricted endogenous presentation of an immunodominant viral epitope.
Deng J; Lu C; Liu C; Oveissi S; Fairlie WD; Lee EF; Bilsel P; Puthalakath H; Chen W
FEBS J; 2021 May; 288(10):3164-3185. PubMed ID: 33830641
[TBL] [Abstract][Full Text] [Related]
6. Activation of human CD4+ T cells by targeting MHC class II epitopes to endosomal compartments using human CD1 tail sequences.
Niazi KR; Ochoa MT; Sieling PA; Rooke NE; Peter AK; Mollahan P; Dickey M; Rabizadeh S; Rea TH; Modlin RL
Immunology; 2007 Dec; 122(4):522-31. PubMed ID: 17635609
[TBL] [Abstract][Full Text] [Related]
7. Predicting CD4 T-cell epitopes based on antigen cleavage, MHCII presentation, and TCR recognition.
Schneidman-Duhovny D; Khuri N; Dong GQ; Winter MB; Shifrut E; Friedman N; Craik CS; Pratt KP; Paz P; Aswad F; Sali A
PLoS One; 2018; 13(11):e0206654. PubMed ID: 30399156
[TBL] [Abstract][Full Text] [Related]
8. Modified vaccinia virus Ankara-infected dendritic cells present CD4+ T-cell epitopes by endogenous major histocompatibility complex class II presentation pathways.
Thiele F; Tao S; Zhang Y; Muschaweckh A; Zollmann T; Protzer U; Abele R; Drexler I
J Virol; 2015 Mar; 89(5):2698-709. PubMed ID: 25520512
[TBL] [Abstract][Full Text] [Related]
9. Influence of strong CD4 epitope on long-term virus-specific cytotoxic T cell responses induced in vivo with peptides.
Sauzet JP; Gras-Masse H; Guillet JG; Gomard E
Int Immunol; 1996 Apr; 8(4):457-65. PubMed ID: 8671632
[TBL] [Abstract][Full Text] [Related]
10. LAMP-2-deficient human B cells exhibit altered MHC class II presentation of exogenous antigens.
Crotzer VL; Glosson N; Zhou D; Nishino I; Blum JS
Immunology; 2010 Nov; 131(3):318-30. PubMed ID: 20518820
[TBL] [Abstract][Full Text] [Related]
11. Unexpected reactivities of T cells selected by a single MHC-peptide ligand.
Singh N; Van Kaer L
J Immunol; 1999 Oct; 163(7):3583-91. PubMed ID: 10490950
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
13. The alloreactive and self-restricted CD4+ T cell response directed against a single MHC class II/peptide combination.
Kovalik JP; Singh N; Mendiratta SK; Martin WD; Ignatowicz L; Van Kaer L
J Immunol; 2000 Aug; 165(3):1285-93. PubMed ID: 10903728
[TBL] [Abstract][Full Text] [Related]
14. Determination of a Predictive Cleavage Motif for Eluted Major Histocompatibility Complex Class II Ligands.
Paul S; Karosiene E; Dhanda SK; Jurtz V; Edwards L; Nielsen M; Sette A; Peters B
Front Immunol; 2018; 9():1795. PubMed ID: 30127785
[TBL] [Abstract][Full Text] [Related]
15. Cellular mechanisms involved in protection against influenza virus infection in transgenic mice expressing a TCR receptor specific for class II hemagglutinin peptide in CD4+ and CD8+ T cells.
Bot A; Casares S; Bot S; von Boehmer H; Bona C
J Immunol; 1998 May; 160(9):4500-7. PubMed ID: 9574556
[TBL] [Abstract][Full Text] [Related]
16. Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.
Dissanayake SK; Tuera N; Ostrand-Rosenberg S
J Immunol; 2005 Feb; 174(4):1811-9. PubMed ID: 15699107
[TBL] [Abstract][Full Text] [Related]
17. Presentation by recycling MHC class II molecules of an influenza hemagglutinin-derived epitope that is revealed in the early endosome by acidification.
Sinnathamby G; Eisenlohr LC
J Immunol; 2003 Apr; 170(7):3504-13. PubMed ID: 12646611
[TBL] [Abstract][Full Text] [Related]
18. Selection of T-cell epitopes from foot-and-mouth disease virus reflects the binding affinity to different cattle MHC class II molecules.
Haghparast A; Wauben MH; Grosfeld-Stulemeyer MC; van Kooten P; Hensen EJ
Immunogenetics; 2000 Jul; 51(8-9):733-42. PubMed ID: 10941845
[TBL] [Abstract][Full Text] [Related]
19. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
20. Measurement of Peptide Binding to MHC Class II Molecules by Fluorescence Polarization.
Yin L; Stern LJ
Curr Protoc Immunol; 2014 Aug; 106():5.10.1-5.10.12. PubMed ID: 25081912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
